Polyrizon reports successful intranasal delivery of PL-14 Allergy Blocker

Polyrizon (PLRZ) announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain platform. The study, conducted in collaboration with the University of Parma, demonstrated targeted deposition in the nasal vestibule-the key anatomical site for early allergen contact-reinforcing the product’s potential as a barrier-forming treatment for allergic rhinitis. The evaluation was led by Professor Fabio Sonvico from the Department of Food and Drug at the University of Parma. Using a validated silicone-based human nasal cast and fluorescein-labeled imaging, the study assessed the spray deposition profile of PL-14 when administered under clinically relevant conditions.